These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17345782)

  • 1. ARBs or ACEIs, that is the question.
    Ishigami T; Uchino K; Umemura S
    Hypertens Res; 2006 Nov; 29(11):837-8. PubMed ID: 17345782
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
    Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF;
    J Nephrol; 2007; 20(6):646-55. PubMed ID: 18046666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Renin Report.
    Sica DA; Ichihara A
    J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):247-51. PubMed ID: 17347934
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 7. Renin-angiotensin system inhibitors for prevention of new-onset atrial fibrillation.
    Baker WL; White CM
    Conn Med; 2007 Apr; 71(4):205-9. PubMed ID: 17487005
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual renin-angiotensin system blockade and kidney disease.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Pfeffer MA
    J Am Coll Cardiol; 2009 Jul; 54(3):278-9; author reply 279-80. PubMed ID: 19589445
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Onuigbo MA
    Nephrol Dial Transplant; 2010 Apr; 25(4):1344-5. PubMed ID: 20037177
    [No Abstract]   [Full Text] [Related]  

  • 10. Moving beyond angiotensin II to also target aldosterone?
    Little WC; Kirkman PM
    J Am Coll Cardiol; 2009 Aug; 54(6):513-4. PubMed ID: 19643311
    [No Abstract]   [Full Text] [Related]  

  • 11. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A; Majkowska L
    Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers: current status and future prospects.
    Kumar S; Ram CV
    Indian Heart J; 2007; 59(6):443-53. PubMed ID: 19151457
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Baweja S; Holt SG; McMahon LP
    Nephrol Dial Transplant; 2011 May; 26(5):1752-3; author reply 1753. PubMed ID: 21471329
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke.
    Angeli F; Gentile G; Reboldi G; Verdecchia P
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1171-4. PubMed ID: 18939903
    [No Abstract]   [Full Text] [Related]  

  • 16. The hazards of dual renin-angiotensin blockade in chronic kidney disease.
    Ku E; Park J; Vidhun J; Campese V
    Arch Intern Med; 2009 Jun; 169(11):1015-8. PubMed ID: 19506167
    [No Abstract]   [Full Text] [Related]  

  • 17. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R; Brown DL
    Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
    Cotter J; Oliveira P; Cunha P; Polónia J
    Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.